▲ 0.20%
prev close
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Congressional Trades
1
All tracked trades
Members Trading
1
Unique members
Net Activity
+1
1 buys · 0 sells
Members Who Traded This Stock
1 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2025-06-09 | SNNSmith & Nephew SNATS, Inc. Common Stock | Buy | $1,001 - $15,000 | 294d ago | — |
2025-06-09
Lisa McClain
SNN
Amount
$1,001 - $15,000
Filed
294d ago
Recent News
Powered by Polygon.io
Wound Irrigation Systems Market to Skyrocket USD 430.05 Million by 2035 as Chronic Wound Cases and Surgical Volumes Rise Worldwide | SNS Insider
Smith+Nephew launch next generation LEAF™ Patient Monitoring System – an innovative pressure injury prevention platform delivering proven clinical impact
Smith+Nephew drives progress in chronic wound care with ALLEVYN™COMPLETE CARE Dressing and RENASYS™ EDGE tNPWT set to launch at EWMA 2026
Wound Cleanser Products Market Size is Projected to be USD 5.17 Billion by 2035; Industry is Propelling Owing to the Growing Technological Investments Globally
Tissue Engineering Market to Grow at 12.95% CAGR Reaching USD 27.59 Billion by 2031, Driven by Advances in Regenerative Medicine and Biomaterials, Says Mordor Intelligence
Trade Timeline
Congressional activity, newest first
Lisa McClain
2025-06-09 · Purchase
$1,001 - $15,000